Close Sidebar
Nordic Life Science
Now Reading
Targovax completes 70 MNOK financing
Search for content, post, videos
Search for content, post, videos
Advertisement

Targovax completes 70 MNOK financing

June 12, 2014
1562 Views

Immunotherapy specialist Targovax has completed a 70 MNOK financing, mainly from new investors.

CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”.

Chairman Jónas Einarsson comments; “This is an important step forward for Targovax, and clearly shows that the Norwegian investment community has opened its eyes to our sector.”

Advertisement

Datum and partners represent the largest new group of shareholders.

Advertisement

Related Posts

Magnus Corfitzen
March 22, 2021

The Issue will provide the company with SEK 200 million before transaction costs. Ascelia Pharma intends to use the net proceeds from the Issue for (i) financing the Phase II study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently…

Evelina Vågesjö Photo Jenny Öhman Nordic Life Science
August 14, 2024

Ilya Pharma has closed a EUR 5 million funding round with mainly existing shareholders including the EIC Fund participating, but also welcoming six new shareholders. The funds are used to advance the company’s portfolio of three first-in-class immunotherapies for skin, gastro and lung indications to the next value adding milestones…

Annette Säfholm
December 22, 2021

Gedea Biotech has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The project goal is to better understand the microbial etiology of bacterial vaginosis (BV) and…

Max IV Photo Kennet Ruona
January 31, 2020

Follicum’s grant application to Vinnova to study binding of FOL peptides to receptors on pancreatic cells has been approved. Follicum is the coordinator of the project, which also includes Lund University and SARomics Biostructures. Parts of the project involve advanced analysis work to be performed  at the new MAX IV…